Genenta Science (NASDAQ:GNTA) Trading Down 0.6% – Here’s Why

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA)’s stock price traded down 0.6% during trading on Wednesday . The stock traded as low as $1.64 and last traded at $1.64. Approximately 61,336 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 118,827 shares. The stock had previously closed at $1.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 10th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Genenta Science Stock Down 0.6%

The stock’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.11. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Eurizon Capital SGR S.p.A. acquired a new stake in Genenta Science during the 4th quarter valued at approximately $536,000. Ghisallo Capital Management LLC acquired a new position in shares of Genenta Science in the 4th quarter valued at approximately $482,000. Weiss Asset Management LP acquired a new position in shares of Genenta Science in the 4th quarter valued at approximately $480,000. Norges Bank purchased a new position in shares of Genenta Science during the 4th quarter valued at approximately $337,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Genenta Science during the 4th quarter valued at approximately $328,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.